Susquehanna International Group
CTMX icon

Susquehanna International Group’s CytomX Therapeutics CTMX Stock Holding History

Susquehanna International Group’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.27M Buy
907,800
+887,200
+4,307% +$4.5M ﹤0.01% 4531
2025
Q4 		$87.8K Sell
20,600
-181,200
-90% -$688K ﹤0.01% 11525
2025
Q3 		$644K Buy
201,800
+186,900
+1,254% +$421K ﹤0.01% 8398
2025
Q2 		$33.8K Buy
+14,900
New +$24K ﹤0.01% 12223
2024
Q3 		– Sell
-15,300
Closed -$18.7K – 12133
2024
Q2 		$18.7K Buy
+15,300
New +$30.5K ﹤0.01% 11678
2023
Q2 		– Sell
-28,000
Closed -$42.3K – 12204
2023
Q1 		$42.3K Buy
+28,000
New +$63.3K ﹤0.01% 11758
2022
Q1 		– Sell
-21,700
Closed -$94K – 13112
2021
Q4 		$94K Sell
21,700
-9,900
-31% -$58K ﹤0.01% 12183
2021
Q3 		$161K Buy
31,600
+4,200
+15% +$22.5K ﹤0.01% 11733
2021
Q2 		$173K Buy
27,400
+6,400
+30% +$49.8K ﹤0.01% 11737
2021
Q1 		$162K Buy
+21,000
New +$166K ﹤0.01% 11589
2018
Q4 		– Sell
-24,800
Closed -$459K – 9060
2018
Q3 		$459K Buy
24,800
+13,400
+118% +$305K ﹤0.01% 6693
2018
Q2 		$261K Buy
+11,400
New +$291K ﹤0.01% 8115

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Susquehanna International Group's CTMX Position: Q1 2026 in Review

Susquehanna International Group increased its CytomX Therapeutics (CTMX) stake by 90% in Q1 2026, buying an estimated $4.51M and bringing the position to 1,869,615 shares worth $8.79M. The position accounts for ﹤0.01% of the portfolio, ranked #3310.

Susquehanna International Group first reported a position in CTMX in Q4 2015 and has held it in 30 quarters since. 179 funds tracked by Wall St. Rank hold CTMX as of Q1 2026.

  • Susquehanna International Group held 1,869,615 shares of CytomX Therapeutics worth $8.79M as of Q1 2026.
  • Susquehanna International Group bought 888,017 CytomX Therapeutics shares in Q1 2026, an estimated $4.51M.
  • CytomX Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #3310 holding.
  • Susquehanna International Group first reported a position in CytomX Therapeutics in Q4 2015 and has held it in 30 quarters since.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.